DOSING REGIMENS FOR THE TREATMENT OF FABRY DISEASE

• 收藏
• 分享

专利权人:

Amicus Therapeutics, Inc.

发明人:

Greene, Douglas Stuart,Valenzano, Kenneth Joseph

申请号：

AU20180201637

公开号：

AU2018201637(A1)

申请日:

2018.03.07

申请国别(地区):

澳大利亚

年份:

2018

代理人:

摘要：

The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxygalactonojirimycin and enzyme replacement therapy for the treatment of Fabry disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of migalastat hydrochloride and agalsidase for the treatment of Fabry disease. Period = ERT Alone -0- 2001-003, 1.0 mg/kg + 2017-001, 0.5 mg/kg 35004+ 2018-001, 0.5 mg/kg -A-2018-002, 1.0 mg/kg 3000- -- 2018-003, 0.5 mg/kg 2500 - + 2018-004, 0.5 mg/kg E 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hr) Period = Co-Administration -0- 2001-003, 1.0 mg/kg+AT1001 150 mg + 2017-001, 0.5 mg/kg+AT1001 150 mg 35004+ 2018-001, 0.5 mg/kg+AT1001 150 mg 30 -A- 2018-002, 1.0 mg/kg+AT1001 150 mg 3000- -- 2018-003, 0.5 mg/kg+AT1001 150 mg 2500- + 2018-004, 0.5 mg/kg+AT1001 150 mg a 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hr)

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/